All In Biotech

Drug Trial Radar · NCT06352632

ACT-GLOBAL Adaptive Platform Trial for Stroke

A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke (ACT-GLOBAL)

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 20,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

20,000

Planned (sponsor's estimate)

Start

Sep 26, 2024

Primary completion

Sep 2034

Study completion Sep 2034

Sponsor

Lead sponsor
The George InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Calgary; Berry Consultants
First posted
Apr 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Stroke is causing 6.6 million deaths and is a major cause of disability worldwide in 2019. There remains an urgent need for interventions that improve outcomes which can be implemented with wide applicability for stroke. ACT-GLOBAL is a multi-factorial, multi-arm, multi-stage, randomised, global adaptive platform trial for stroke, aiming to identify the treatment/s associated with the highest chance of improving outcome in stroke patients. In ACT-GLOBAL multiple questions will be evaluated simultaneously and sequentially as data accrues and can evaluate interactions between different treatment options.

Conditions

  • Stroke

Interventions

  • Standard-dose intravenous tenecteplaseDrug

    Standard-dose intravenous tenecteplase (0.25 mg/kg body weight); one-time IV bolus injection soon after randomisation

  • Low-dose intravenous tenecteplaseDrug

    Low-dose intravenous tenecteplase (0.18 mg/kg body weight); one-time IV bolus injection soon after randomisation

  • No intravenous tenecteplaseOther

    No intravenous tenecteplase only in subjects on direct oral anticoagulant (DOACs) or those planned for emergency endovascular thrombectomy (EVT)

  • Conservative Blood Pressure ControlOther

    No or minimal Systolic Blood Pressure (SBP) control; SBP reduction by 5-10mmHg or a target of 175-180mmHg if very-high baseline SBP (≥180mmHg); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)

  • Moderate Blood Pressure ControlOther

    SBP reduction by 10-20mmHg or a target of 160 ± 5, whichever is higher; no control if low-high baseline SBP (150-160mmHg); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)

  • Intensive Blood Pressure ControlOther

    SBP reduction by 30-50mmHg or a target of 140±5 mmHg, whichever is higher after endovascular thrombectomy (EVT); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)

  • PlaceboOther

    100 mL of 0.9% normal saline, administered as a single IV infusion with a 20-minute dosing duration.

  • NoNO-42Drug

    NoNO-42 at weight-based dosing - 2.6 mg/Kg, administered as a single IV infusion with a 20-minute dosing duration

  • No deferoxamine mesylate and no colchicineOther

    No deferoxamine mesylate and no colchicine

  • Deferoxamine mesylate onlyDrug

    Deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days

  • Colchicine onlyDrug

    0.5mg of oral colchicine daily for 30 days

  • Both deferoxamine mesylate and colchicineDrug

    Deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days; plus 0.5mg of oral colchicine daily for 30 consecutive days

  • IA thrombolysisDrug

    Participants randomised to the IA thrombolysis group will receive IA thrombolysis (tenecteplase or alteplase) at the time of completion of the mechanical thrombectomy part of the EVT procedure. Tenecteplase will be given at a dose of 0.0625mg/kg (maximum dose of 6.25mg) and alteplase at a dose of 0.225 mg/kg (maximum dose 22.5mg) intraarterially by the treating neuro-interventional staff. The selection of thrombolytic agent will be determined according to local availability. The study drug dose will be increased to 0.125 mg/ kg (maximum dose 12.5mg) for tenecteplase or 0.45 mg/kg (maximum dose 40mg) for alteplase if above dose meet prespecified posterior probabilities at the first or second interims per adaptive design report.

  • no IA thrombolysisOther

    Participants randomised to the No IA thrombolysis group will not receive IA thrombolysis.

  • IMP-ACT usual careOther

    Usual medical and stroke-unit care, including intravenous thrombolysis when eligible. This is the usual-care strategy in IMP-ACT (NCT07906275), without assigned mechanical endovascular thrombectomy or adjunctive intra-arterial thrombolysis.

  • IMP-ACT mechanical endovascular thrombectomyProcedure

    Mechanical endovascular thrombectomy (EVT) using tools and techniques selected by the treating neurointerventionalist. This procedure is used in both EVT strategies in IMP-ACT (NCT07906275); the EVT-alone strategy does not include intra-arterial thrombolysis.

  • Intra-arterial tenecteplase or alteplase in IMP-ACTDrug

    Adjunctive intra-arterial tenecteplase or alteplase delivered by microcatheter into the affected arterial territory following mechanical endovascular thrombectomy. The agent is selected according to local availability. This intervention is used only in the EVT-plus-intra-arterial-thrombolysis strategy. Regimen details are specified in the IMP-ACT domain registration (NCT07906275).

  • CoPRIME aspirin aloneDrug

    Aspirin 160 mg on day 1, followed by 81 mg once daily on days 2-21. Study treatment starts within 60 minutes of randomization. This is the aspirin-alone strategy in CoPRIME.

  • CoPRIME aspirin plus clopidogrelDrug

    Aspirin 160 mg plus clopidogrel 300 mg on day 1, followed by aspirin 81 mg once daily plus clopidogrel 75 mg once daily on days 2-21. Study treatment starts within 60 minutes of randomization. This is the aspirin-plus-clopidogrel strategy in CoPRIME.

  • CoPRIME aspirin plus ticagrelorDrug

    Aspirin 160 mg plus ticagrelor 180 mg on day 1, followed by aspirin 81 mg once daily plus ticagrelor 90 mg twice daily on days 2-21. Study treatment starts within 60 minutes of randomization. This is the aspirin-plus-ticagrelor strategy in CoPRIME.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. modified Rankin scale (mRS) scoresTime frame: Platform level time frame: 90 days in Ischaemic Stroke State; 6 months in Intracerebral Haemorrhage State; Domain specific time frame may differ (details will be included in domain-specific registration)

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • The George Institute for Global Health

    Sydney, New South Wales, Australia · Recruiting

  • University of Calgary

    Calgary, Alberta, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.